Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4586803 | 0.81 | CPA1 (0.43) | — | |
| SCHEMBL4594271 | 0.81 | CPA1 (0.43) | — | |
| SCHEMBL4589374 | 0.74 | MAPT (0.38) | PTGS2ALDH1A1 | |
| SCHEMBL4593304 | 0.74 | PTGS2 (0.33) | PTGS2ALDH1A1 | |
| SCHEMBL4587407 | 0.74 | ALDH1A1 (0.42) | PTGS2ALDH1A1 | |
| SCHEMBL4587301 | 0.70 | ARG1 (0.35) | — | |
| SCHEMBL4585809 | 0.68 | PTGS2 (0.48) | PTGS2ALDH1A1 | |
| SCHEMBL7861529 | 0.67 | CTSK (0.40) | — | |
| SCHEMBL16268430 | 0.67 | PTGS2 (0.54) | PTGS2ALDH1A1 | |
| SCHEMBL4586109 | 0.67 | PTGS2 (0.35) | PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | claimed |
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | PTGS2 177/4885ALDH1A1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.